For athletes with chronic degenerative tendinopathy unresponsive to conservative treatment, cell therapy offers a potentially tissue-preserving alternative to surgery (tendon repair or reconstruction). For acute tears in young athletes, early exploration of cell therapy may prevent long-term fibrotic weakening, though the evidence is still preliminary.
Tendons are specialised collagenous tissues that transmit muscle force to bone with minimal elasticity—a design that makes them prone to partial tears and degeneration when overstressed. Unlike muscle, tendons have poor intrinsic healing capacity due to limited blood supply and sparse resident cell populations. Recovery from tendon injury often stalls at a fibrotic scar that is weaker and less organised than native tissue. Cell therapy approaches employ placental MSCs, exosomes (acellular vesicles carrying molecular signals), and sometimes engineered chondrocytes to promote tissue remodelling and fibril alignment. The proposed mechanism involves delivering cells or their secreted factors directly to the injury site, where they are thought to reduce inflammation, promote angiogenesis (new blood vessel formation), and guide collagen deposition along physiologically correct orientations.
Suis-je un candidat? → · Tendon & Sports Injuries: full overview → · Coût Lésions Tendineuses et Blessures Sportives → · Cost →
Médicalement examiné par l'équipe éditoriale de StemCellAtlas avec Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) de la clinique partenaire Stem Plus (Sofia), selon les directives ISSCR, FDA et EMA. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite